Market Overview:
The global therapeutic enzymes market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The oral segment is expected to dominate the market with a share of 94% in 2018. The gastrointestinal diseases segment is expected to be the fastest-growing application segment, with a CAGR of 8.8% from 2018 to 2030. North America is estimated to hold the largest share of the global therapeutic enzymes market in 2018, followed by Europe and Asia Pacific.
Product Definition:
Therapeutic enzymes are used to treat medical conditions. They are usually derived from plants or animals and are used to help the body digest food, absorb nutrients, and fight infection. Therapeutic enzymes can also be used to break down scar tissue and help wounds heal.
Injectable:
Injectable is a form of enzyme therapy that delivers enzymes directly into the bloodstream. It's major advantages are improved absorption and bioavailability, reduced dosage frequency, and increased patient convenience. These factors have led to an increase in their adoption rate over other forms of enzyme therapy which include oral formulations as well as transdermal patches.
Oral:
Oral enzymes are proteins that are found in the saliva of humans and other organisms. These enzymes act as catalysts to speed up certain chemical reactions inside the human body. The most commonly used enzyme is protease which is used for protein breakdown, but there are many others like amylase, lipase, cellulose etc. that have different functions in the human body depending on their types and locations in it (endogenous or exogenous).
Application Insights:
The gastrointestinal diseases segment held the largest share of Therapeutic Enzymes application in 2018. This is due to factors such as high prevalence of colorectal cancer, Crohn¢â‚¬â„¢s disease and ulcerative colitis. In addition, new drug developments for treatment of various gastrointestinal disorders are some other major factor driving the global market growth. For instance, in June 2017 Fonterra Brands Ltd announced that its investigational product ZINPLAVA was granted Orphan Designation by European Commission (EC) for use in treating Ulcerative Colitis (UC).
MPS disease is expected to be the fastest growing segment over the forecast period owing to increasing incidence rates and awareness programs launched by regulatory authorities regarding this condition.
Regional Analysis:
North America dominated the global market in 2018. This can be attributed to the presence of a large number of patients suffering from MPS and Gaucher disease, increased healthcare expenditure, better reimbursement policies for therapeutic enzymes and high awareness among people related to these diseases. In addition, new product launches are also expected to drive growth during the forecast period. For instance, in May 2019 Pfizer Inc launched Trobalt tablets for treatment of MPS II (Gaucher) disease in U.S.
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. The rise in the number of people suffering from chronic diseases has led to an increase in the demand for therapeutic enzymes.
- Growing awareness about benefits of therapeutic enzymes: There is a growing awareness among people about the benefits of using therapeutic enzymes for treating various health conditions. This is helping to drive demand for these products worldwide.
- Technological advancements in enzyme therapy: There have been significant advancements in enzyme therapy over the past few years, owing to which this segment is expected to grow at a rapid pace in the coming years. Enzyme therapies are becoming more sophisticated and are being used to treat a wider range of medical conditions than ever before.
Scope Of The Report
Report Attributes
Report Details
Report Title
Therapeutic Enzymes Market Research Report
By Type
Injectable, Oral, Topical, Oral had the biggest market share of 94% in 2018.
By Application
Gaucher Disease, MPS Disease, Gastrointestinal Diseases, Others, MPS Disease is the greatest segment of Therapeutic Enzymes application, with a share of 22% in 2018.
By Companies
Sanofi, BioMarin, AbbVie, Shire, Alexion, Horizon Pharma, Allergan, Johnson & Johnson, Recordati Rare Diseases, Pfizer, Vivus, Digestive Care, Leadiant Biosciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Therapeutic Enzymes Market Report Segments:
The global Therapeutic Enzymes market is segmented on the basis of:
Types
Injectable, Oral, Topical, Oral had the biggest market share of 94% in 2018.
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Gaucher Disease, MPS Disease, Gastrointestinal Diseases, Others, MPS Disease is the greatest segment of Therapeutic Enzymes application, with a share of 22% in 2018.
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- BioMarin
- AbbVie
- Shire
- Alexion
- Horizon Pharma
- Allergan
- Johnson & Johnson
- Recordati Rare Diseases
- Pfizer
- Vivus
- Digestive Care
- Leadiant Biosciences
Highlights of The Therapeutic Enzymes Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injectable
- Oral
- Topical
- Oral had the biggest market share of 94% in 2018.
- By Application:
- Gaucher Disease
- MPS Disease
- Gastrointestinal Diseases
- Others
- MPS Disease is the greatest segment of Therapeutic Enzymes application, with a share of 22% in 2018.
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Therapeutic Enzymes Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Therapeutic enzymes are proteins that help to break down molecules in the body. These proteins can be found in supplements, food, and even some medications. Therapeutic enzymes can help to improve digestion, relieve pain and inflammation, and support the immune system.
Some of the major players in the therapeutic enzymes market are Sanofi, BioMarin, AbbVie, Shire, Alexion, Horizon Pharma, Allergan, Johnson & Johnson, Recordati Rare Diseases, Pfizer, Vivus, Digestive Care, Leadiant Biosciences.
The therapeutic enzymes market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Therapeutic Enzymes Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Therapeutic Enzymes Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Therapeutic Enzymes Market - Supply Chain
4.5. Global Therapeutic Enzymes Market Forecast
4.5.1. Therapeutic Enzymes Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Therapeutic Enzymes Market Size (000 Units) and Y-o-Y Growth
4.5.3. Therapeutic Enzymes Market Absolute $ Opportunity
5. Global Therapeutic Enzymes Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Therapeutic Enzymes Market Size and Volume Forecast by Type
5.3.1. Injectable
5.3.2. Oral
5.3.3. Topical
5.3.4. Oral had the biggest market share of 94% in 2018.
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Therapeutic Enzymes Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Therapeutic Enzymes Market Size and Volume Forecast by Application
6.3.1. Gaucher Disease
6.3.2. MPS Disease
6.3.3. Gastrointestinal Diseases
6.3.4. Others
6.3.5. MPS Disease is the greatest segment of Therapeutic Enzymes application, with a share of 22% in 2018.
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Therapeutic Enzymes Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Therapeutic Enzymes Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Therapeutic Enzymes Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Therapeutic Enzymes Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Therapeutic Enzymes Demand Share Forecast, 2019-2026
9. North America Therapeutic Enzymes Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Therapeutic Enzymes Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Therapeutic Enzymes Market Size and Volume Forecast by Application
9.4.1. Gaucher Disease
9.4.2. MPS Disease
9.4.3. Gastrointestinal Diseases
9.4.4. Others
9.4.5. MPS Disease is the greatest segment of Therapeutic Enzymes application, with a share of 22% in 2018.
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Therapeutic Enzymes Market Size and Volume Forecast by Type
9.7.1. Injectable
9.7.2. Oral
9.7.3. Topical
9.7.4. Oral had the biggest market share of 94% in 2018.
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Therapeutic Enzymes Demand Share Forecast, 2019-2026
10. Latin America Therapeutic Enzymes Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Therapeutic Enzymes Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Therapeutic Enzymes Market Size and Volume Forecast by Application
10.4.1. Gaucher Disease
10.4.2. MPS Disease
10.4.3. Gastrointestinal Diseases
10.4.4. Others
10.4.5. MPS Disease is the greatest segment of Therapeutic Enzymes application, with a share of 22% in 2018.
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Therapeutic Enzymes Market Size and Volume Forecast by Type
10.7.1. Injectable
10.7.2. Oral
10.7.3. Topical
10.7.4. Oral had the biggest market share of 94% in 2018.
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Therapeutic Enzymes Demand Share Forecast, 2019-2026
11. Europe Therapeutic Enzymes Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Therapeutic Enzymes Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Therapeutic Enzymes Market Size and Volume Forecast by Application
11.4.1. Gaucher Disease
11.4.2. MPS Disease
11.4.3. Gastrointestinal Diseases
11.4.4. Others
11.4.5. MPS Disease is the greatest segment of Therapeutic Enzymes application, with a share of 22% in 2018.
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Therapeutic Enzymes Market Size and Volume Forecast by Type
11.7.1. Ijectable
11.7.2. Oral
11.7.3. Topical
11.7.4. Oral had the biggest market share of 94% in 2018.
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Therapeutic Enzymes Demand Share, 2019-2026
12. Asia Pacific Therapeutic Enzymes Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Therapeutic Enzymes Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Therapeutic Enzymes Market Size and Volume Forecast by Application
12.4.1. Gaucher Disease
12.4.2. MPS Disease
12.4.3. Gastrointestinal Diseases
12.4.4. Others
12.4.5. MPS Disease is the greatest segment of Therapeutic Enzymes application, with a share of 22% in 2018.
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Therapeutic Enzymes Market Size and Volume Forecast by Type
12.7.1. Injectable
12.7.2. Oral
12.7.3. Topical
12.7.4. Oral had the biggest market share of 94% in 2018.
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Therapeutic Enzymes Demand Share, 2019-2026
13. Middle East & Africa Therapeutic Enzymes Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Therapeutic Enzymes Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Therapeutic Enzymes Market Size and Volume Forecast by Application
13.4.1. Gaucher Disease
13.4.2. MPS Disease
13.4.3. Gastrointestinal Diseases
13.4.4. Others
13.4.5. MPS Disease is the greatest segment of Therapeutic Enzymes application, with a share of 22% in 2018.
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Therapeutic Enzymes Market Size and Volume Forecast by Type
13.7.1. Injectable
13.7.2. Oral
13.7.3. Topical
13.7.4. Oral had the biggest market share of 94% in 2018.
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Therapeutic Enzymes Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Therapeutic Enzymes Market: Market Share Analysis
14.2. Therapeutic Enzymes Distributors and Customers
14.3. Therapeutic Enzymes Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sanofi
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. BioMarin
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. AbbVie
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Shire
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Alexion
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Horizon Pharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Allergan
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Johnson & Johnson
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Recordati Rare Diseases
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Pfizer
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Vivus
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Digestive Care
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Leadiant Biosciences
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
